Several bDMARDs have recently emerged in RA management, including TNF-α inhibitors (TNFi) as adalimumab, etanercept, and infliximab; IL-6 receptor antibody, such as tocilizumab; and JAK inhibitors (JAKi) as tofacitinib (Guo et al., 2018; Smolen et al., 2020). This evidence concerns the gene TNF and rheumatoid arthritis.